SCHEMBL23217831

SCHEMBL23217831

COc1c(CO)cc(Br)c2occc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
CYP1A1 P04798 3/20 0.43
CYP1A2 P05177 3/20 0.43
CYP1B1 Q16678 3/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 2/20 0.42
ALOX15 P16050 1/20 0.42
CYP2D6 P10635 1/20 0.42
PDE4A P27815 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KCNA3 P22001 11/20 0.41
KCNA2 P16389 1/20 0.39
KCNA4 P22459 1/20 0.39
KCNA5 P22460 1/20 0.39
KCNA1 Q09470 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217660 0.87 KCNA3 (0.36) CYP3A4CYP1A1CYP1A2CYP1B1HPGD
SCHEMBL23217647 0.86 CYP3A4 (0.44) CYP3A4CYP1A1CYP1A2CYP1B1HPGD
SCHEMBL23217816 0.84 HTR2A (0.34) CYP3A4CYP1A1CYP1A2CYP1B1HPGD
SCHEMBL21438255 0.80 HTR2A (0.33) CYP3A4CYP1A2HPGDKDM4EPOLB
SCHEMBL23217812 0.79 PTGDR2 (0.45) KDM4EPOLBALDH1A1ALOX15KCNA3
SCHEMBL21437650 0.76 HTR2A (0.33)
SCHEMBL23217270 0.76 KCNA2 (0.40) KCNA3KCNA2KCNA4KCNA5KCNA1
SCHEMBL23241702 0.76 KDM4E (0.39) CYP1A1HPGDKDM4EPOLBALDH1A1
SCHEMBL30009732 0.76 KDM4E (0.39) CYP1A1HPGDKDM4EPOLBALDH1A1
SCHEMBL28772736 0.76 HTR2A (0.36) KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
CN-114555570-B Oral complement factor D inhibitors 拜奥克里斯特制药公司 2024-09-13 CN disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CYP3A4 643/4885CYP1A1 2008/4885CYP1A2 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.